26-Jun-2026
Early Data Milestone: BeOne Medicines Advances BGB-15025 in Immune Oncology
TipRanks (Fri, 26-Jun 12:31 PM ET)
BeOne Medicines Insiders Quietly Unload Major Stakes in High-Profile Stock Move
TipRanks (Thu, 25-Jun 10:01 PM ET)
BeOne Medicines’ Real-World Lung Cancer Study Puts Tislelizumab Under the Market Microscope
TipRanks (Thu, 25-Jun 12:31 PM ET)
Business Wire (Fri, 12-Jun 6:00 AM ET)
Business Wire (Thu, 11-Jun 7:24 AM ET)
BeOne Medicines Highlights Accelerating Solid Tumor Pipeline with New Data at ASCO 2026
Business Wire (Mon, 1-Jun 6:00 AM ET)
Business Wire (Fri, 29-May 6:00 AM ET)
ONC's Phase 3 HERIZON-GEA Study Shows Seven-Month Survival Gain in HER2+ Gastroesophageal Cancer
Market Chameleon (Thu, 28-May 3:08 AM ET)
BeOne Medicines Announces Phase 3 HERIZON-GEA Data Published in NEJM and Presented at ASCO 2026
Business Wire (Wed, 27-May 5:00 PM ET)
BeOne Medicines to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
Business Wire (Tue, 26-May 6:01 AM ET)
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
Beone Medicines Ltd. - American Depositary Shares trades on the NASDAQ stock market under the symbol ONC.
As of June 26, 2026, ONC stock price climbed to $279.89 with 321,027 million shares trading.
ONC has a beta of 0.59, meaning it tends to be less sensitive to market movements. ONC has a correlation of 0.03 to the broad based SPY ETF.
ONC has a market cap of $29.04 billion. This is considered a Large Cap stock.
Last quarter Beone Medicines Ltd. - American Depositary Shares reported $2 billion in Revenue and $3.24 earnings per share. This beat revenue expectation by $72 million and exceeded earnings estimates by $2.45.
The top ETF exchange traded funds that ONC belongs to (by Net Assets): IBB, FBT, CGGE, CGIE, BBH.
ONC has underperformed the market in the last year with a return of +10.0%, while the SPY ETF gained +20.4%. In the last 3 month period, ONC fell short of the market, returning +1.1%, while SPY returned +13.3%. However, in the most recent 2 weeks ONC has outperformed the stock market by returning +5.8%, while SPY returned -1.5%.
ONC support price is $269.96 and resistance is $280.72 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ONC shares will trade within this expected range on the day.